Fulcrum Therapeutics Inc. shares rose 15% on Tuesday, extending gains from the prior session amid elevated trading volume.
The biotechnology company’s stock advanced throughout the day, closing at $2.85, up from Monday’s close of $2.48. Volume exceeded 12 million shares, well above the 30-day average of roughly 1.1 million, according to market data.
No new corporate announcements, clinical trial updates, regulatory filings or earnings reports were released to coincide with the move. The company has not commented on the trading activity or provided additional context for the price action.
Analysts attributed the surge to speculative trading activity, noting the stock’s low float and historical volatility. Fulcrum Therapeutics, which focuses on gene regulation therapies for rare diseases, has seen its shares fluctuate sharply in recent months, reflecting broader volatility in the biotech sector.
The stock’s recent performance follows a broader trend of retail investor-driven rallies in smaller-cap biotech names, often without fundamental catalysts. Investors should exercise caution, as such moves can reverse quickly without warning.
